These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22530662)

  • 1. A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine.
    Ham JC; Hoogendijk-van den Akker JM; Verdonck LF
    Leuk Lymphoma; 2012 Dec; 53(12):2521-2. PubMed ID: 22530662
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes.
    Silverman LR
    Cancer Control; 2004; 11(6 Suppl):11-5. PubMed ID: 15625532
    [No Abstract]   [Full Text] [Related]  

  • 3. Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine.
    Yoshioka A; Fujiwara S; Kawano H; Nakano H; Taketani S; Matsui T; Katayama Y; Nishigori C
    Acta Derm Venereol; 2018 Feb; 98(2):275-277. PubMed ID: 29057424
    [No Abstract]   [Full Text] [Related]  

  • 4. Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.
    List A
    Cancer Control; 2004; 11(6 Suppl):16-9. PubMed ID: 15625533
    [No Abstract]   [Full Text] [Related]  

  • 5. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
    Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
    Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and adverse events of azacitidine in the treatment of hemodialysis patients with high-risk myelodysplastic syndrome].
    Yoshihiro T; Muta T; Aoki K; Shimamoto S; Tamura Y; Ogawa R
    Rinsho Ketsueki; 2016 Aug; 57(8):1004-10. PubMed ID: 27599416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine is effective for the treatment of myelodysplastic syndrome and accompanied Sweet syndrome.
    Lin CH; Yeh SP; Lin TY
    Ann Hematol; 2015 Nov; 94(11):1925-6. PubMed ID: 26233682
    [No Abstract]   [Full Text] [Related]  

  • 8. [Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine].
    Kudo D; Shimizu M; Kuroda A; Suyama T; Shinagawa A; Ito S
    Rinsho Ketsueki; 2017; 58(6):607-612. PubMed ID: 28679990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes.
    Follo MY; Finelli C; Bosi C; Martinelli G; Mongiorgi S; Baccarani M; Manzoli L; Blalock WL; Martelli AM; Cocco L
    Leukemia; 2008 Jan; 22(1):198-200. PubMed ID: 17625605
    [No Abstract]   [Full Text] [Related]  

  • 10. Disseminated varicella-zoster virus infection following azacitidine in a patient with myelodysplastic syndrome.
    Zhou G; Houldin AD
    Clin J Oncol Nurs; 2009 Jun; 13(3):280-4. PubMed ID: 19502185
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
    DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
    Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of late onset erythropoietic protoporphyria associated with myelodysplastic syndrome treated by the combination of beta carotene and azacitidine.
    Nishikawa Y; Okuda S; Takebayashi C; Tanimoto T; Kami M; Kobayashi K
    Ann Hematol; 2013 Oct; 92(10):1415-6. PubMed ID: 23475052
    [No Abstract]   [Full Text] [Related]  

  • 13. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
    Voso MT; Santini V; Finelli C; Musto P; Pogliani E; Angelucci E; Fioritoni G; Alimena G; Maurillo L; Cortelezzi A; Buccisano F; Gobbi M; Borin L; Di Tucci A; Zini G; Petti MC; Martinelli G; Fabiani E; Fazi P; Vignetti M; Piciocchi A; Liso V; Amadori S; Leone G
    Clin Cancer Res; 2009 Aug; 15(15):5002-7. PubMed ID: 19638460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
    Kantarjian HM
    J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
    [No Abstract]   [Full Text] [Related]  

  • 15. Image Gallery: Pyoderma gangrenosum in a patient with myelodysplastic syndrome treated with azacitidine.
    Pardo Pastor J; Redondo Capafons S; March López P; Nicolás Picó J; Pineda A; Martí JM
    Br J Dermatol; 2017 Sep; 177(3):e68. PubMed ID: 28940271
    [No Abstract]   [Full Text] [Related]  

  • 16. Interstitial granulomatous dermatitis associated with myelodysplastic syndrome - complete clearance under therapy with 5-azacytidine.
    Patsinakidis N; Susok L; Hessam S; Othlinghaus N; Möllenhoff K; Stücker M; Altmeyer P; Kreuter A
    Acta Derm Venereol; 2014 Nov; 94(6):725-6. PubMed ID: 24573709
    [No Abstract]   [Full Text] [Related]  

  • 17. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
    Chou WC; Yeh SP; Hsiao LT; Lin SF; Chen YC; Chen TY; Laille E; Galettis A; Dong Q; Songer S; Beach CL
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e430-e439. PubMed ID: 28124500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.